DE69736351T4 - Methoden und mittel zur hemmung der cdk4-aktivität - Google Patents

Methoden und mittel zur hemmung der cdk4-aktivität Download PDF

Info

Publication number
DE69736351T4
DE69736351T4 DE69736351T DE69736351T DE69736351T4 DE 69736351 T4 DE69736351 T4 DE 69736351T4 DE 69736351 T DE69736351 T DE 69736351T DE 69736351 T DE69736351 T DE 69736351T DE 69736351 T4 DE69736351 T4 DE 69736351T4
Authority
DE
Germany
Prior art keywords
peptide
fragment
cdk4
amino acid
cyclin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736351T
Other languages
German (de)
English (en)
Other versions
DE69736351T2 (de
DE69736351D1 (de
Inventor
CRC Cell Transform. Res. Group Kathryn L. BALL
CRC Cell Transform. Res. Group David P. LANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of DE69736351T2 publication Critical patent/DE69736351T2/de
Application granted granted Critical
Publication of DE69736351T4 publication Critical patent/DE69736351T4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69736351T 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität Expired - Lifetime DE69736351T4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9609521 1996-05-08
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use
GB9621314 1996-10-09
PCT/GB1997/001250 WO1997042222A1 (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Publications (2)

Publication Number Publication Date
DE69736351T2 DE69736351T2 (de) 2007-07-12
DE69736351T4 true DE69736351T4 (de) 2009-07-23

Family

ID=26309279

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69736351T Expired - Lifetime DE69736351T4 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität
DE69736351A Expired - Fee Related DE69736351D1 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69736351A Expired - Fee Related DE69736351D1 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität

Country Status (7)

Country Link
US (3) US6962792B1 (enExample)
EP (1) EP0898580B9 (enExample)
JP (1) JP4205165B2 (enExample)
AT (1) ATE333465T1 (enExample)
AU (1) AU2707797A (enExample)
DE (2) DE69736351T4 (enExample)
WO (1) WO1997042222A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736351T4 (de) 1996-05-08 2009-07-23 Cyclacel Ltd. Methoden und mittel zur hemmung der cdk4-aktivität
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
CA2321480A1 (en) * 1998-02-18 1999-08-26 Laurence Anthony Seabra Treating cancer
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
AU3103599A (en) * 1998-03-23 1999-10-18 E.I. Du Pont De Nemours And Company Plant cell cyclin genes
AU762006B2 (en) * 1998-12-24 2003-06-19 Ucb Peptidic product, process and composition
AU4203300A (en) * 1999-04-07 2000-10-23 E.I. Du Pont De Nemours And Company Cell cycle genes in plants
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
CA2494236A1 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. Csnk1gs as modifiers of the p21 pathway and methods of use
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
EP1687331A1 (en) * 2003-10-20 2006-08-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
CA2542880A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
EP1909811B1 (en) * 2005-06-29 2012-02-01 St. George's Enterprises Limited Hox peptides as pbx modulators for the treatment of cancer
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
EP0665886B1 (en) 1992-10-16 2003-06-11 Cold Spring Harbor Laboratory Cyclin complex rearrangement and uses related thereto
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
EP0723402B1 (en) 1993-08-30 2010-08-18 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
WO1997003681A1 (en) 1995-07-20 1997-02-06 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
DE69736351T4 (de) 1996-05-08 2009-07-23 Cyclacel Ltd. Methoden und mittel zur hemmung der cdk4-aktivität

Also Published As

Publication number Publication date
EP0898580B9 (en) 2009-08-12
DE69736351T2 (de) 2007-07-12
EP0898580B1 (en) 2006-07-19
WO1997042222A1 (en) 1997-11-13
EP0898580A1 (en) 1999-03-03
US6962792B1 (en) 2005-11-08
ATE333465T1 (de) 2006-08-15
DE69736351D1 (de) 2006-08-31
AU2707797A (en) 1997-11-26
EP0898580B3 (en) 2008-10-29
US20080249025A1 (en) 2008-10-09
JP4205165B2 (ja) 2009-01-07
JP2000513805A (ja) 2000-10-17
US20040214765A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE69736351T2 (de) Methoden und mittel zur hemmung der cdk4-aktivität
DE60123041T2 (de) Entzündungshemmende verbindungen und ihre verwendung
DE69233399T2 (de) Menschliches cyclin e
DE69605934T2 (de) Cyclin-abhängige kinase bindende verbindungen
DE69533255T2 (de) ISOLIERTES p27 PROTEIN UND NUKLEINSÄURE DAFÜR KODIEREND
EP1003786B1 (de) Peptid mit radioprotektiver wirkung
DE69636365T2 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
DE69839326T2 (de) ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB
DE69835215T2 (de) Inhibitoren von phosphoserin- und phosphothreoninspezifischen isomerasen
Matsumine et al. MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase
EP0926236A1 (de) Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie
EP0786004B1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3-kinase
DE69712878T2 (de) Phosphatasemodulator
DE60216048T2 (de) Screeningverfahren für Peptide, die die Bindung von PP1c an Bcl-2, BCL-Xl und BCL-W Proteine inhibieren
DE69931140T2 (de) Hemmung der angiogenese durch peptidanaloge der kininogen domäne 5mit hohem molekulargewicht
DE69305348T2 (de) Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung
DE69513025T2 (de) Test für inhibitoren von dp-1 und anderen dp-proteinen
DE69837808T2 (de) pRb2/p130 PEPTIDINHIBITOREN DER cdk2 KINASEAKTIVITÄT
DE69424747T2 (de) Pharmazeutische Zusammensetzung zur Vorbeugung oder Behandlung von Knochenbrüchen
DE69731682T2 (de) TAB1 Protein und dafür kodierende DNA
DE69707001T2 (de) Ein zellfreies system zum start der dna replikation
DE60217711T2 (de) Ptp10d nukleinsäuren und peptide in der regulation von energie-homeostase
DE19842863A1 (de) Regulatorisches Protein aus humanen Keratinozyten
DE19837015C2 (de) Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
DE69925281T2 (de) Testverfahren zum modulieren von nukleärer lokalisierung